General Information
Revision date
2021-04-15
Product name
Litex Two-component adhesive component A
CAS No.
65997-15-1
Emergency telephone
Comment
Icons in SDS
Company Information
company name
Litex AS
e-mail address of the competent person responsible for the Safety Data Sheet
post@litex.no
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H315, H318, H335
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
CLP CLASSIFICATION
Skin Irrit. 2 H315 Eye Dam. 1 H318 STOT SE 3 H335
Hazard statements
see section 16 : H315 - Causes skin irritation. H318 - Causes serious eye damage. H335 - May cause respiratory irritation.
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling according to Regulation (EC) No. 1272/2008 [CLP]
Hazard pictograms
GHS05 GHS07
Signal word
Danger
Contains
Portland cement
Precautionary statements
P261 - Avoid breathing dust/fume/gas/mist/vapours/spray. P280 - Wear protective gloves, eye protection, face protection. P302+P352 - IF ON SKIN: Wash with plenty of water. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 - Immediately call a POISON CENTER or doctor. P332+P313 - If skin irritation occurs: Get medical advice/attention. P271 - Use only outdoors or in a well-ventilated area.
Additional information
The product is classified on the basis of information from the manufacturer.
Other hazards which do not result in classification
Dust of the product, if present, may cause respiratory irritation after an excessive inhalation exposure. This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605